A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: The international oncology study group CML1 study

Basit Öğe Kaydı
dc.authorscopusid34568568400
dc.authorscopusid59028785900
dc.authorscopusid35268179500
dc.authorscopusid36037983800
dc.authorscopusid58393073200
dc.authorscopusid7003418466
dc.authorscopusid6602651217
dc.contributor.authorGiles F.J.
dc.contributor.authorShan J.
dc.contributor.authorChen S.
dc.contributor.authorAdvani S.H.
dc.contributor.authorSupandiman I.
dc.contributor.authorAziz Z.
dc.contributor.authorCaviles A.P.
dc.date.accessioned2024-08-04T20:00:44Z
dc.date.available2024-08-04T20:00:44Z
dc.date.issued2000
dc.departmentİnönü Üniversitesien_US
dc.description.abstractA prospective randomized international study of 143 patients showed no apparent early survival advantage conferred by combining cytarabine, rather than hydroxyurea, with INF as first-line CML therapy. Combinations of alpha-interferon (INF) and chemotherapeutic agents are currently first-line therapy for the majority of patients with chronic myeloid leukemia (CML). The International Oncology Study Group conducted a prospective randomized study comparing INF combined with hydroxyurea or cytarabine. The primary study aim was to compare the survival durations in these patient cohorts. Patients with early chronic phase CML were randomized to receive INF 5 million units (Mu) given five times per week subcutaneously plus hydroxyurea or cytarabine as required to achieve a complete hematologic response and to maintain a WBC count between 2 x 109/L and 10 x 109/L and a platelet count between 75 x 109/L and 100 x 109/L. Therapy continued as tolerated unless progressive or blast phase disease occurred. At 36 months, the actuarial survival rate was equivalent in both groups: HI group (79 patients) survival was 85% (95% CI, 68-100%), as compared to 95% (95% CI, 79-100%) in the CI group (64 patients). In conclusion if seems that there is no apparent early survival advantage conferred by combining cytarabine, rather than hydroxyurea, with INF as first-line CML therapy.en_US
dc.identifier.doi10.3109/10428190009089437
dc.identifier.endpage377en_US
dc.identifier.issn1042-8194
dc.identifier.issue3-4en_US
dc.identifier.pmid10752988en_US
dc.identifier.scopus2-s2.0-0034066911en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage367en_US
dc.identifier.urihttps://doi.org/10.3109/10428190009089437
dc.identifier.urihttps://hdl.handle.net/11616/90949
dc.identifier.volume37en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHarwood Academic Publishers GmbHen_US
dc.relation.ispartofLeukemia and Lymphomaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCML hydroxyureaen_US
dc.subjectCytarabineen_US
dc.subjectInterferonen_US
dc.subjectSurvivalen_US
dc.titleA prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: The international oncology study group CML1 studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu